Related Experiment Video
Updated: May 4, 2026
07:46
Using the Activity-based Anorexia Rodent Model to Study the Neurobiological Basis of Anorexia Nervosa
Published on: October 22, 2015
15.2K
Adiponectin in eating disorders.
Rami Bou Khalil1, Charline El Hachem
1Saint Joseph University, Beirut, Lebanon, ramiboukhalil@hotmail.com.
Eating and Weight Disorders : EWD
|December 31, 2013
Summary
Adiponectin, a fat-secreted hormone, may play a role in eating disorders. Levels are high in anorexia nervosa and low in binge eating disorder, suggesting a complex relationship needing further research.
Area of Science:
- Endocrinology
- Neuroscience
- Psychiatry
Background:
- Adiponectin is an adipokine from white adipose tissue.
- It influences the neuromodulation of food intake.
Purpose of the Study:
- To investigate the role of adiponectin in the pathogenesis of eating disorders.
- To review existing literature on adiponectin and eating disorders.
Main Methods:
- Comprehensive literature review using MedLine.
- Search terms included "adiponectin" combined with specific eating disorder terms.
Main Results:
- Elevated serum adiponectin in anorexia nervosa, normalizing with refeeding.
- Variable adiponectin levels in bulimia nervosa (equal, higher, or lower than controls).
- Lower serum adiponectin in binge eating disorder; Adiponectin receptor type 1 implicated.
Conclusions:
- Adiponectin's role in eating disorder pathogenesis requires further investigation.
- More research is needed to fully elucidate adiponectin's complex involvement.
Related Concept Videos
01:30Regulation of Food Intake
2.8K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.8K
01:28Anorexia Nervosa
2.0K
Anorexia nervosa is a complex and severe eating disorder characterized by an intense fear of weight gain, an unrelenting pursuit of thinness, and a distorted body image. It often leads to dangerously low body weight relative to an individual's age and height. This disorder is marked by significant physical and psychological consequences, making it one of the most life-threatening psychiatric illnesses.
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
2.0K
01:23Binge Eating Disorders
828
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
828
01:30Bulimia Nervosa
1.1K
Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
1.1K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K